4.50Open4.50Pre Close129 Volume182 Open Interest20.00Strike Price57.38KTurnover281.81%IV30.67%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier22DDays to Expiry4.40Extrinsic Value100Contract SizeAmericanOptions Type-0.3017Delta0.0224Gamma4.95Leverage Ratio-0.1237Theta-0.0062Rho-1.49Eff Leverage0.0192Vega
Jasper Therapeutics Stock Discussion
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet